MULTI-ETHNIC STUDY OF ATHEROSCLEROSIS (MESA)

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。动脉粥样硬化的多种族研究(MESA)是由NHLBI资助的一项为期10年的亚临床心血管疾病(在产生体征和症状之前非侵入性检测到的疾病)的多中心研究。这项研究的总体目标是确定亚临床动脉粥样硬化者的特征，这些特征可以预测进展为临床心脏病事件。这项研究的具体目标是：确定与临床心脏病相关的特征；确定亚临床疾病的新衡量标准；以及开发识别高风险无症状人群的方法，以便在未来的筛查和干预研究中应用。我们将通过作为现场中心参与一项合作的、多中心的队列研究来实现这些目标，研究对象为年龄在45-84岁之间、没有临床心血管疾病证据的基线人群。在研究的头18个月期间，我们目前正在参与协作性议定书的制定和试点研究阶段。我们将从2000年夏天开始在WFUSM现场中心招募1100名福赛斯县成年人(包括50%的非裔美国人)。参与者将使用一系列技术程序接受亚临床心血管疾病的评估。这些数据对于更好地设计未来的临床和基于人群的干预计划，以进一步减轻美国心血管疾病的负担将是重要的。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The Multi-Ethnic Study of Atherosclerosis (MESA) is a 10-year NHLBI-funded multi-center study of subclinical cardiovascular disease (disease detected non-invasively before it has produced signs and symptoms). The overall goal of this study is to identify characteristics of persons with subclinical atherosclerosis that predict progression to clinical heart disease events. The specific aims of this study are: to determine characteristics related to clinical heart disease; to identify new measures of subclinical disease; and to develop methods for identifying the highest risk asymptomatic persons for application in future screening and intervention studies. We will accomplish these aims by participating as a field center in a collaborative, multi-center, cohort study of persons ages 45-84 years without evidence of clinical cardiovascular disease at baseline. We are currently participating in the collaborative protocol development and the pilot study phase, during the first 18 months of the study. We will begin recruiting 1,100 Forsyth County adults at the WFUSM field center (including 50% African Americans) beginning in the Summer of 2000. Participants will be evaluated for subclinical cardiovascular disease using a number of technologic procedures. These data will be important to better design future clinical and population-based intervention programs to further reduce the burden of cardiovascular disease in the United States.